American Bio Medica Competitors

Novelion Therapeutics (OTCMKTS:NVLNF) and American Bio Medica (OTCMKTS:ABMC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

This table compares Novelion Therapeutics and American Bio Medica's revenue, earnings per share and valuation.

American Bio Medica has lower revenue, but higher earnings than Novelion Therapeutics.

Profitability

This table compares Novelion Therapeutics and American Bio Medica's net margins, return on equity and return on assets.

Risk and Volatility

Novelion Therapeutics has a beta of 2.15, indicating that its stock price is 115% more volatile than the S&P 500. Comparatively, American Bio Medica has a beta of -1.45, indicating that its stock price is 245% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Novelion Therapeutics and American Bio Medica, as provided by MarketBeat.

Insider & Institutional Ownership

48.6% of Novelion Therapeutics shares are held by institutional investors. 3.6% of Novelion Therapeutics shares are held by company insiders. Comparatively, 13.0% of American Bio Medica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Novelion Therapeutics beats American Bio Medica on 5 of the 8 factors compared between the two stocks.

Intec Pharma (NASDAQ:NTEC) and American Bio Medica (OTCMKTS:ABMC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Profitability

This table compares Intec Pharma and American Bio Medica's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and price targets for Intec Pharma and American Bio Medica, as provided by MarketBeat.

Intec Pharma currently has a consensus price target of $13.00, indicating a potential upside of 239.43%. Given Intec Pharma's higher possible upside, research analysts clearly believe Intec Pharma is more favorable than American Bio Medica.

Earnings & Valuation

This table compares Intec Pharma and American Bio Medica's top-line revenue, earnings per share and valuation.

American Bio Medica has higher revenue and earnings than Intec Pharma.

Summary

American Bio Medica beats Intec Pharma on 4 of the 7 factors compared between the two stocks.

Nuvo Pharmaceuticals (OTCMKTS:NRIFF) and American Bio Medica (OTCMKTS:ABMC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Profitability

This table compares Nuvo Pharmaceuticals and American Bio Medica's net margins, return on equity and return on assets.

Volatility & Risk

Nuvo Pharmaceuticals has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, American Bio Medica has a beta of -1.45, meaning that its share price is 245% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Nuvo Pharmaceuticals and American Bio Medica, as provided by MarketBeat.com.

Earnings and Valuation

This table compares Nuvo Pharmaceuticals and American Bio Medica's gross revenue, earnings per share (EPS) and valuation.

Nuvo Pharmaceuticals has higher revenue and earnings than American Bio Medica.

Summary

Nuvo Pharmaceuticals beats American Bio Medica on 6 of the 7 factors compared between the two stocks.

Medicure (OTCMKTS:MCUJF) and American Bio Medica (OTCMKTS:ABMC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Earnings and Valuation

This table compares Medicure and American Bio Medica's revenue, earnings per share (EPS) and valuation.

American Bio Medica has lower revenue, but higher earnings than Medicure.

Analyst Ratings

This is a summary of current recommendations and price targets for Medicure and American Bio Medica, as reported by MarketBeat.com.

Risk & Volatility

Medicure has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, American Bio Medica has a beta of -1.45, suggesting that its stock price is 245% less volatile than the S&P 500.

Profitability

This table compares Medicure and American Bio Medica's net margins, return on equity and return on assets.

Summary

American Bio Medica beats Medicure on 5 of the 7 factors compared between the two stocks.

American Bio Medica (OTCMKTS:ABMC) and CannaPharmaRX (OTCMKTS:CPMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for American Bio Medica and CannaPharmaRX, as provided by MarketBeat.com.

Risk and Volatility

American Bio Medica has a beta of -1.45, suggesting that its stock price is 245% less volatile than the S&P 500. Comparatively, CannaPharmaRX has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.

Earnings and Valuation

This table compares American Bio Medica and CannaPharmaRX's top-line revenue, earnings per share and valuation.

American Bio Medica has higher revenue and earnings than CannaPharmaRX.

Profitability

This table compares American Bio Medica and CannaPharmaRX's net margins, return on equity and return on assets.

Summary

American Bio Medica beats CannaPharmaRX on 4 of the 6 factors compared between the two stocks.

American Bio Medica (OTCMKTS:ABMC) and CannaPharmaRX (OTCMKTS:CPMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for American Bio Medica and CannaPharmaRX, as provided by MarketBeat.com.

Valuation and Earnings

This table compares American Bio Medica and CannaPharmaRX's top-line revenue, earnings per share and valuation.

American Bio Medica has higher revenue and earnings than CannaPharmaRX.

Profitability

This table compares American Bio Medica and CannaPharmaRX's net margins, return on equity and return on assets.

Risk & Volatility

American Bio Medica has a beta of -1.45, suggesting that its share price is 245% less volatile than the S&P 500. Comparatively, CannaPharmaRX has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.

Summary

American Bio Medica beats CannaPharmaRX on 4 of the 6 factors compared between the two stocks.